BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

This study has been completed.
Information provided by:
Boehringer Ingelheim Identifier:
First received: February 18, 2009
Last updated: August 4, 2009
Last verified: August 2009

February 18, 2009
August 4, 2009
February 2009
July 2009   (final data collection date for primary outcome measure)
The primary efficacy variable will be (FEV1). The coprimary efficacy endpoints are FEV1 AUC 0 to 12 and FEV1 AUC 12 to 24 after 3 weeks of treatment. [ Time Frame: up to 3 weeks of treatment ]
Same as current
Complete list of historical versions of study NCT00846768 on Archive Site
Efficacy endpoints Efficacy after 3 weeks of treatment: FEV1 and FVC AUC 0 to 24, peak FEV1and FVC and trough FEV1 and FVC;individual FEV1 and FVC measurements at each time point over 24 hours. Safety: AE, vital signs, lab, ECG pK plasma and urine [ Time Frame: up to 3 weeks of treatment ]
Same as current
Not Provided
Not Provided
BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD
Randomised, Double-Blind, Cross-over Study to Determine the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, Delivered With the Respimat Inhaler, After 3 Weeks of Once Daily or Twice Daily Administration in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The primary objective of the trial is to determine the effect of BI 17444Cl on the lung function over a 24-hour period, when it is inhaled using the Respimat inhaler in patients with chronic obstructive pulmonary disease. In the trial four treatments of each 3 weeks of duration are included: 2 dosages in a once daily administration and 2 dosages for administration twice daily.

Not Provided
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Pulmonary Disease, Chronic Obstructive
Drug: BI 1744 CL
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions
  2. All patients must have a diagnosis of COPD and must meet the following spirometric criteria:

    Patients must have relatively stable airway obstruction with a post-bronchodilator FEV1 < 80% of predicted normal and a post-bronchodilator FEV1 / FVC < 70% at Visit 1

  3. Male or female patients, 40 years of age or older
  4. Patients must be current or ex-smokers with a smoking history of more than 10 pack years
  5. Patients must be able to perform technically acceptable pulmonary function tests
  6. Patients must be able to inhale medication in a competent manner from the Respimat inhaler and from a metered dose inhaler (MDI).

Exclusion Criteria:

  1. Patients with a significant disease other than COPD.
  2. Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT > x2 ULN, SGPT > x2 ULN, bilirubin > x2 ULN or creatinine > x2 ULN will be excluded regardless of clinical condition.
  3. Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma. If a patient has a total blood eosinophil count more than 600/mm3, source documentation is required to verify that the increased eosinophil count is related to a non-asthmatic condition.
  4. Patients with any respiratory infection or COPD exacerbation in the 6 weeks prior to the Screening Visit (Visit 1) or during the baseline period.
  5. Patients with any of the following conditions: a diagnosis of thyrotoxicosis; a diagnosis of paroxysmal tachycardia (>100 beats per minute)
  6. Patients with any of the following conditions: a history of myocardial infarction within 1 year of screening visit (Visit 1); unstable or life-threatening cardiac arrhythmia; have been hospitalized for heart failure within the past year; known active tuberculosis; a malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed); a history of life-threatening pulmonary obstruction; a history of cystic fibrosis; clinically evident bronchiectasis; a history of significant alcohol or drug abuse
  7. Patients who have undergone thoracotomy with pulmonary resection
  8. Patients being treated with any of the following concomitant medications: oral beta2-adrenergics; oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
  9. Patients who regularly use daytime oxygen therapy for more than one hour per day.
  10. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program
  11. Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to Screening Visit
  12. Patients with known hypersensitivity to beta-adrenergics drugs, BAC, EDTA or any other component of the Respimat inhalation solution delivery system
  13. Pregnant or nursing women
  14. Women of childbearing potential not using two effective methods of birth control (one barrier, one non-barrier). Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years
  15. Patients who have previously been randomized in this study or are currently participating in another study
  16. Patients who are unable to comply with pulmonary medication restrictions prior to randomization
40 Years and older
Contact information is only displayed when the study is recruiting subjects
Belgium,   Netherlands
1222.26, EudtaCT No: 2008-006334-10
Not Provided
Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP